• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Exalenz & ALF Study Group ink deal for BreathID acute liver failure study

Exalenz & ALF Study Group ink deal for BreathID acute liver failure study

March 14, 2016 By Fink Densford

Exalenz BiosciencesExalenz Biosciences said today it inked a collaborative deal with the Acute Liver Failure Study Group to support a study of the BreathID methacetin breath test’s ability to predict outcomes in patients with acute liver failure.

The trial is slated to enroll 200 ALF patients over 2 years across 12 sites in the U.S. to test the newly FDA investigative device exemption-approved BreathID, Israel-based Exalenz said.

“We are looking forward to assessing the technological abilities of BreathID and how it can improve physician decision making when treating ALF patients. Over the years, the ALF Study Group has been able to better understand ALF disease progression and to improve patient survival dramatically. We believe that the breath test information can potentially supply an additional tool to diagnose these critically ill patients, and the BreathID prove technologically beneficial in disease progression prediction,”ALFSG founder & study lead Dr. William Lee said in a press release.

ALF patients are typically monitored in ICUs with clinical and laboratory tests which Exalenz said are often insufficient to determine whether a liver transplant is required or if recovery can be expected.

In the study, which is supported by the National Institute of Health’s National Institute of Diabetes and Digestive and Kidney Diseases, patients will receive 5 breath tests during their 1st week of hospitalization. An earlier study in 2013 reported that BreathID breath test results provided important information to assist in predicting rapid deterioration and the need for liver transplant.

“We are pleased to announce this collaboration with the leading group of ALF researchers. This study is another important step in evaluating the advantages of BreathID as a non-invasive and accurate diagnostic and monitoring tool with lifesaving potential, in the broad field of liver disease,” Exalenz BioScience CEO Raffi Werner said in prepared remarks.

Exalenz said the study is part of a growing series of investigational diagnostic aplication studies using the BreathID to diagnose serious liver conditions.

Filed Under: Business/Financial News, Clinical Trials, Diagnostics Tagged With: Exalenz Biosciences

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy